检测和鉴定加拿大异质性万古霉素中介金黄色葡萄球菌分离株：加拿大医院感染监测计划，1995-2006 年的结果。
Detection and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1995-2006.
机构信息
Department of Laboratory Medicine & Pathobiology, University of Toronto, and Hospital for Sick Children, Toronto, Ontario, Canada.
出版信息
Antimicrob Agents Chemother. 2010 Feb;54(2):945-9. doi: 10.1128/AAC.01316-09. Epub 2009 Nov 30.
Abstract
We describe the epidemiology of heterogeneously resistant Staphylococcus aureus (hVISA) identified in Canadian hospitals between 1995 and 2006. hVISA isolates were confirmed by the population analysis profiling-area under the curve method. Only 25 hVISA isolates (1.3% of all isolates) were detected. hVISA isolates were more likely to have been health care associated (odds ratio [OR], 5.1; 95% confidence interval [CI], 1.9 to 14.2) and to have been recovered from patients hospitalized in central Canada (OR, 3.0; 95% CI, 1.2 to 7.4). There has been no evidence of vancomycin "MIC creep" in Canadian strains of methicillin (meticillin)-resistant S. aureus, and hVISA strains are currently uncommon.
摘要
我们描述了 1995 年至 2006 年间在加拿大医院中发现的异质性万古霉素中介金黄色葡萄球菌（hVISA）的流行病学情况。通过群体分析谱-曲线下面积方法确认 hVISA 分离株。仅检测到 25 株 hVISA 分离株（所有分离株的 1.3%）。hVISA 分离株更可能与医疗保健相关（比值比[OR]，5.1；95%置信区间[CI]，1.9 至 14.2），并且更可能从加拿大中部住院患者中分离出来（OR，3.0；95%CI，1.2 至 7.4）。加拿大耐甲氧西林金黄色葡萄球菌（meticillin）菌株中没有万古霉素“MIC 攀升”的证据，并且 hVISA 菌株目前并不常见。
相似文献
1
Detection and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1995-2006.检测和鉴定加拿大异质性万古霉素中介金黄色葡萄球菌分离株：加拿大医院感染监测计划，1995-2006 年的结果。
Antimicrob Agents Chemother. 2010 Feb;54(2):945-9. doi: 10.1128/AAC.01316-09. Epub 2009 Nov 30.
2
Molecular epidemiology and clinical characteristics of hetero-resistant vancomycin intermediate Staphylococcus aureus bacteremia in a Taiwan Medical Center.台湾一家医学中心耐异质性万古霉素中介金黄色葡萄球菌菌血症的分子流行病学和临床特征。
J Microbiol Immunol Infect. 2012 Dec;45(6):435-41. doi: 10.1016/j.jmii.2012.05.004. Epub 2012 Jun 30.
3
Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant S. aureus with high vancomycin minimal inhibitory concentrations in Taiwan: A multicenter surveillance study, 2012-2013.台湾地区高万古霉素最小抑菌浓度的耐甲氧西林金黄色葡萄球菌中万古霉素中介金黄色葡萄球菌（VISA）和异质性 VISA 的流行情况：一项 2012-2013 年多中心监测研究。
J Microbiol Immunol Infect. 2016 Oct;49(5):701-707. doi: 10.1016/j.jmii.2015.07.003. Epub 2015 Jul 31.
4
Prevalence and molecular characteristics of heterogeneous vancomycin intermediate Staphylococcus aureus in a tertiary care center of northern China.中国北方一家三级医院中异质性万古霉素中介金黄色葡萄球菌的流行及分子特征。
Diagn Microbiol Infect Dis. 2024 Mar;108(3):116180. doi: 10.1016/j.diagmicrobio.2024.116180. Epub 2024 Jan 4.
5
Evaluation of the Presence and Characterization of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Level Resistance Among Bloodstream Isolates of Methicillin-Resistant .评估耐甲氧西林金黄色葡萄球菌血流分离株中万古霉素中介和异质性万古霉素中介水平耐药的存在和特征。
Microb Drug Resist. 2020 Mar;26(3):238-244. doi: 10.1089/mdr.2019.0178. Epub 2019 Sep 23.
6
Detection of heterogeneous vancomycin-intermediate : A preliminary report from south India.印度南部地区异质性万古霉素中介的检测：初步报告。
Indian J Med Res. 2019 Aug;150(2):194-198. doi: 10.4103/ijmr.IJMR_1976_17.
7
Activities of vancomycin, ceftaroline, and mupirocin against Staphylococcus aureus isolates collected in a 2011 national surveillance study in the United States.万古霉素、头孢洛林和莫匹罗星对 2011 年美国全国监测研究中分离的金黄色葡萄球菌的活性。
Antimicrob Agents Chemother. 2014;58(2):740-5. doi: 10.1128/AAC.01915-13. Epub 2013 Nov 18.
8
Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.中国14个城市异质性万古霉素中介金黄色葡萄球菌分离株的流行情况及特征
Antimicrob Agents Chemother. 2009 Sep;53(9):3642-9. doi: 10.1128/AAC.00206-09. Epub 2009 Jun 22.
9
Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years.万古霉素最低抑菌浓度加异质性耐药与耐甲氧西林金黄色葡萄球菌菌血症的转归：11年趋势
J Clin Microbiol. 2009 Jun;47(6):1640-4. doi: 10.1128/JCM.02135-08. Epub 2009 Apr 15.
10
The Prevalence of Vancomycin-Intermediate Staphylococcus aureus and Heterogeneous VISA Among Methicillin-Resistant Strains Isolated from Pediatric Population in a Turkish University Hospital.土耳其某大学医院分离出的耐甲氧西林菌株中万古霉素中介金黄色葡萄球菌和异质性万古霉素中介金黄色葡萄球菌的患病率
Microb Drug Resist. 2015 Oct;21(5):537-44. doi: 10.1089/mdr.2015.0048. Epub 2015 Apr 28.
引用本文的文献
1
Diagnostic value of BHI-V4 for heterogeneous and vancomycin-intermediate Staphylococcus aureus isolates: a systematic review and meta-analysis.BHI-V4 对异质性和万古霉素中介金黄色葡萄球菌分离株的诊断价值：系统评价和荟萃分析。
BMC Infect Dis. 2024 May 14;24(1):494. doi: 10.1186/s12879-024-09274-4.
2
Molecular characterization of methicillin-resistant Staphylococcus aureus genotype ST764-SCCmec type II in Thailand.泰国耐甲氧西林金黄色葡萄球菌 ST764-SCCmec 型 II 基因型的分子特征。
Sci Rep. 2022 Feb 8;12(1):2085. doi: 10.1038/s41598-022-05898-1.
3
[Strategies on the prevention and treatment of surgical site infection and the resulting wound].手术部位感染及所致伤口的防治策略
Zhonghua Shao Shang Za Zhi. 2021 Mar 20;37(3):207-212. doi: 10.3760/cma.j.cn501120-20210105-00006.
4
Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis.万古霉素耐药、万古霉素中介和异质性万古霉素中介金黄色葡萄球菌临床分离株的全球流行率和分布：系统评价和荟萃分析。
Sci Rep. 2020 Jul 29;10(1):12689. doi: 10.1038/s41598-020-69058-z.
5
Detection of heterogeneous vancomycin intermediate resistance in MRSA isolates from Latin America.检测拉丁美洲耐甲氧西林金黄色葡萄球菌分离株中的异质性万古霉素中介耐药。
J Antimicrob Chemother. 2020 Sep 1;75(9):2424-2431. doi: 10.1093/jac/dkaa221.
6
Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.成人医院获得性肺炎和呼吸机相关性肺炎的管理：美国感染病学会和美国胸科学会2016年临床实践指南
Clin Infect Dis. 2016 Sep 1;63(5):e61-e111. doi: 10.1093/cid/ciw353. Epub 2016 Jul 14.
7
Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates.万古霉素中介及异质性万古霉素中介金黄色葡萄球菌分离株流行病学的系统评价与荟萃分析
PLoS One. 2015 Aug 19;10(8):e0136082. doi: 10.1371/journal.pone.0136082. eCollection 2015.
8
Antimicrobial heteroresistance: an emerging field in need of clarity.抗菌异质性耐药：一个亟待明确的新兴领域。
Clin Microbiol Rev. 2015 Jan;28(1):191-207. doi: 10.1128/CMR.00058-14.
9
Characterization of methicillin-resistant Staphylococcus aureus isolates from patients with persistent or recurrent bacteremia.耐甲氧西林金黄色葡萄球菌分离株的特征，这些分离株来自持续性或复发性菌血症患者。
Can J Infect Dis Med Microbiol. 2014 Mar;25(2):83-6. doi: 10.1155/2014/853482.
10
Vancomycin and daptomycin minimum inhibitory concentration distribution and occurrence of heteroresistance among methicillin-resistant Staphylococcus aureus blood isolates in Turkey.万古霉素和达托霉素最低抑菌浓度分布及土耳其耐甲氧西林金黄色葡萄球菌血分离株异质性耐药的发生。
BMC Infect Dis. 2013 Dec 10;13:583. doi: 10.1186/1471-2334-13-583.
本文引用的文献
1
Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA.异质性万古霉素中介耐甲氧西林金黄色葡萄球菌（MRSA）与万古霉素敏感MRSA临床影响的前瞻性比较。
Antimicrob Agents Chemother. 2009 Aug;53(8):3447-52. doi: 10.1128/AAC.01365-08. Epub 2009 Jun 8.
2
Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years.万古霉素最低抑菌浓度加异质性耐药与耐甲氧西林金黄色葡萄球菌菌血症的转归：11年趋势
J Clin Microbiol. 2009 Jun;47(6):1640-4. doi: 10.1128/JCM.02135-08. Epub 2009 Apr 15.
3
Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia.异质性万古霉素中介金黄色葡萄球菌菌血症与耐甲氧西林金黄色葡萄球菌菌血症的临床特征比较
J Infect Dis. 2009 Mar 1;199(5):619-24. doi: 10.1086/596629.
4
Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides.评估Etest GRD用于检测对糖肽类敏感性降低的金黄色葡萄球菌的性能。
J Antimicrob Chemother. 2009 Mar;63(3):489-92. doi: 10.1093/jac/dkn520. Epub 2009 Jan 9.
5
Incidence and characteristics of vancomycin nonsusceptible strains of methicillin-resistant Staphylococcus aureus at Hershey Medical Center.赫尔希医疗中心耐甲氧西林金黄色葡萄球菌万古霉素不敏感菌株的发生率及特征
Antimicrob Agents Chemother. 2008 Dec;52(12):4510-3. doi: 10.1128/AAC.01073-08. Epub 2008 Oct 6.
6
Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007).1986年至2007年期间，密歇根州底特律市大都市区耐万古霉素金黄色葡萄球菌的特征分析。
J Clin Microbiol. 2008 Sep;46(9):2950-4. doi: 10.1128/JCM.00582-08. Epub 2008 Jul 16.
7
Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA.评估一种用于检测糖肽类中介金黄色葡萄球菌（GISA），特别是异质性GISA的新型Etest万古霉素-替考拉宁试纸条。
J Clin Microbiol. 2008 Sep;46(9):3042-7. doi: 10.1128/JCM.00265-08. Epub 2008 Jul 2.
8
Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage.在万古霉素使用量较低的情况下，2002年至2006年期间金黄色葡萄球菌分离株的万古霉素最低抑菌浓度没有上升。
J Antimicrob Chemother. 2008 Oct;62(4):773-5. doi: 10.1093/jac/dkn246. Epub 2008 Jun 13.
9
CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting.疾病控制与预防中心/国家医疗安全网络（CDC/NHSN）对医疗保健相关感染的监测定义以及急性护理环境中特定类型感染的标准。
Am J Infect Control. 2008 Jun;36(5):309-32. doi: 10.1016/j.ajic.2008.03.002.
10
Infection control and antimicrobial restriction practices for antimicrobial-resistant organisms in Canadian tertiary care hospitals.加拿大三级护理医院对抗菌药物耐药菌的感染控制及抗菌药物限制措施
Am J Infect Control. 2007 Nov;35(9):563-8. doi: 10.1016/j.ajic.2006.12.003.
Zotero 插件